{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:36:19Z","timestamp":1793136979659,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.eclinm.2026.104190","type":"journal-article","created":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T17:25:36Z","timestamp":1788629136000},"page":"104190","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Short-term versus long-course neoadjuvant chemotherapy for resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results from the second randomisation analysis of a randomised, open-label, 2 \u00d7 2 factorial phase 3 trial"],"prefix":"10.1016","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6463-0293","authenticated-orcid":false,"given":"Michele","family":"Reni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8458-4394","authenticated-orcid":false,"given":"Giulia","family":"Orsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3374-4220","authenticated-orcid":false,"given":"Catia","family":"Carconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Malleo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letizia","family":"Procaccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Macchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Bencardino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Merelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Pretta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1802-5671","authenticated-orcid":false,"given":"Ilario Giovanni","family":"Rapposelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0883-8196","authenticated-orcid":false,"given":"Nicol\u00f2","family":"Pecorelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8938-6170","authenticated-orcid":false,"given":"Stefano","family":"Partelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Sperti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Crippa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Liscia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3470-9494","authenticated-orcid":false,"given":"Mariacristina","family":"Di Marco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Milella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7593-8138","authenticated-orcid":false,"given":"Sara","family":"Lonardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7906-540X","authenticated-orcid":false,"given":"Diego","family":"Palumbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9541-9354","authenticated-orcid":false,"given":"Valter","family":"Torri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9654-7243","authenticated-orcid":false,"given":"Massimo","family":"Falconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.eclinm.2026.104190_bib1","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"10.1016\/j.eclinm.2026.104190_bib2","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jamaoncol.2022.3829","article-title":"Five-year outcomes of FOLFIRINOX vs gemcitabine as adjuvant therapy for pancreatic cancer","volume":"8","author":"Conroy","year":"2022","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.eclinm.2026.104190_bib3","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1001\/jamaoncol.2022.7358","article-title":"Overall survival with adjuvant mFOLFIRINOX for pancreatic cancer","volume":"9","author":"Reni","year":"2023","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104190_bib4","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/SLA.0000000000006730","article-title":"Neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer","volume":"283","author":"Unno","year":"2026","journal-title":"Ann Surg"},{"issue":"12","key":"10.1016\/j.eclinm.2026.104190_bib5","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1016\/j.ccell.2025.09.009","article-title":"Neoadjuvant nab-paclitaxel plus gemcitabine followed by modified FOLFIRINOX for resectable pancreatic cancer: a randomized phase 3 trial","volume":"43","author":"Bai","year":"2025","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.eclinm.2026.104190_bib6","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S2468-1253(18)30081-5","article-title":"Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2\u20133 trial","volume":"3","author":"Reni","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104190_bib7","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.annonc.2022.09.161","article-title":"Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)\u2014A randomized phase II trial of the AIO pancreatic cancer group","volume":"34","author":"Seufferlein","year":"2023","journal-title":"Ann Oncol"},{"issue":"17","key":"10.1016\/j.eclinm.2026.104190_bib8","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO-24-01378","article-title":"Neoadjuvant FOLF(IRIN)OX chemotherapy for resectable pancreatic adenocarcinoma: a multicenter randomized noncomparative phase II trial (PANACHE01 FRENCH08 PRODIGE48 study)","volume":"43","author":"Schwarz","year":"2025","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.eclinm.2026.104190_bib9","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1200\/JCO.21.02233","article-title":"Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the Dutch randomized PREOPANC trial","volume":"40","author":"Versteijne","year":"2022","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.eclinm.2026.104190_bib10","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S2468-1253(22)00348-X","article-title":"Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial","volume":"8","author":"Ghaneh","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.eclinm.2026.104190_bib11","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S2468-1253(23)00405-3","article-title":"Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial","volume":"9","author":"Labori","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.eclinm.2026.104190_bib12","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/S1470-2045(25)00363-8","article-title":"Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial","volume":"26","author":"Janssen","year":"2025","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.eclinm.2026.104190_bib13","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jamaoncol.2020.7328","article-title":"Efficacy of perioperative chemotherapy for resectable pancreatic adenocarcinoma","volume":"7","author":"Sohal","year":"2021","journal-title":"JAMA Oncol"},{"issue":"10522","key":"10.1016\/j.eclinm.2026.104190_bib14","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1016\/S0140-6736(25)01685-X","article-title":"Preoperative mFOLFIRINOX versus PAXG for stage I\u2013III resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results of the first randomisation analysis of a randomised, open-label, 2 \u00d7 2 factorial phase 3 trial","volume":"406","author":"Reni","year":"2026","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.eclinm.2026.104190_bib15","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1245\/s10434-020-09149-3","article-title":"Total neoadjuvant therapy for operable pancreatic cancer","volume":"28","author":"Kim","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.eclinm.2026.104190_bib16","doi-asserted-by":"crossref","first-page":"202","DOI":"10.6004\/jnccn.2019.0014","article-title":"Guidelines insights: pancreatic adenocarcinoma, version 1.2019","volume":"17","author":"Tempero","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104190_bib17","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.pan.2017.11.011","article-title":"International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017","volume":"18","author":"Isaji","year":"2018","journal-title":"Pancreatology"},{"issue":"2","key":"10.1016\/j.eclinm.2026.104190_bib18","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.eclinm.2026.104190_bib19","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1002\/cncr.24302","article-title":"Carbohydrate antigen 19-9 change during chemotherapy for advanced pancreatic adenocarcinoma","volume":"115","author":"Reni","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.eclinm.2026.104190_bib20","volume":"1","year":"1990"},{"issue":"2","key":"10.1016\/j.eclinm.2026.104190_bib21","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2307\/2530862","article-title":"Testing for qualitative interactions between treatment effects and patient subsets","volume":"41","author":"Gail","year":"1985","journal-title":"Biometrics"},{"issue":"6","key":"10.1016\/j.eclinm.2026.104190_bib22","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1245\/s10434-022-11363-0","article-title":"Systemic therapy for resected pancreatic adenocarcinoma: how much is enough?","volume":"29","author":"Turner","year":"2022","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"10.1016\/j.eclinm.2026.104190_bib23","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35759","article-title":"Chemotherapy dose density is prognostic for overall survival in patients with resectable pancreas cancer: a landmark analysis of SWOG 1505","volume":"131","author":"Patel","year":"2025","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.eclinm.2026.104190_bib24","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00280-020-04047-7","article-title":"Time to CA19-9 nadir: a clue for defining optimal treatment duration in patients with resectable pancreatic ductal adenocarcinoma","volume":"85","author":"Reni","year":"2020","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"10.1016\/j.eclinm.2026.104190_bib25","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.hpb.2025.12.018","article-title":"Effect of duration of neoadjuvant therapy on pancreatic cancer outcomes: a systematic review and meta-analysis","volume":"28","author":"Hajibandeh","year":"2026","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.eclinm.2026.104190_bib26","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1038\/s41598-020-57930-x","article-title":"CA19-9 for detecting recurrence of pancreatic cancer","volume":"10","author":"Azizian","year":"2020","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104190_bib27","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jamasurg.2024.5024","article-title":"Routine imaging or symptomatic Follow-Up after resection of pancreatic adenocarcinoma","volume":"160","author":"Andel","year":"2025","journal-title":"JAMA Surg"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026004438?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026004438?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:31:48Z","timestamp":1793136708000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537026004438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":27,"alternative-id":["S2589537026004438"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.104190","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Short-term versus long-course neoadjuvant chemotherapy for resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results from the second randomisation analysis of a randomised, open-label, 2 \u00d7 2 factorial phase 3 trial","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.104190","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104190"}}